GHIT FUND
ANNUAL REPORT 2015

WE ARE EXPANDING.
WE ARE ON THE GROUND.
WE WILL DELIVER.

AN UNYIELDING ETHOS

Letter from Chair and CEO

We are pleased to report noteworthy progress, from the frontiers of discovery to the frontlines of global health, as a result of our work.
We are expanding: our portfolio and partners are more diverse and driven than ever.
We are on the ground: clinical trials in high-burden countries are under way for many of our invested innovations.
We will deliver: critically needed innovations steadily moving through our pipeline will be delivered to patients.

Kiyoshi Kurokawa, MD
Board Chair
BT Slingsby, MD, PhD, MPH
Chief Executive Officer

GHIT COMMITTED INVESTMENT

leveraged

96

OUR PORTFOLIO

Disease
Intervention
Development
Stage
Malaria
34.8%
Tuberculosis
21.5%
NTDs
43.7%
Drugs
62.2%
Vaccines
30.1%
Diagnostics
7.7%
Discovery
20.7%
Preclinical
37.9%
Clinical
41.4%

One important reason I support GHIT is its effective engagement of
Japanese pharmaceutical companies; their involvement in and contributions to
global health activities carry great benefits.

Bill Gates

Co-chair, Bill & Melinda Gates Foundation

EXPANDING GLOBAL NETWORK

  • 64
    Partnerships Funded
  • 36
    Japanese Organizations
  • 41
    Non-Japanese Organizations

WE ARE ON THE GROUND

Six potential global health products currently being advanced
with GHIT investment are on the ground.

NEW PARTNERS, NEW PROMISE

Our expansion process has accelerated, and we are
honored to welcome additional commitments from multiple new partners and sponsors.

FY 2015 -
  • sysmexc
  • wellcometrust
  • ANA
  • MORRISON FOERSTER
  • YAHOO!JAPAN
FY 2016 -
  • FUJIFILM
  • gsk
  • Johnson & Johnson
  • KYOWA KIRIN
  • MERCK
-

We proactively work on development of testing technologies and product development to contribute to the diagnosis of infectious diseases in developing countries. Through the support for the GHIT Fund, we look forward to helping strengthen the R&D effort against infectious diseases prevalent in developing countries.

Hisashi Ietsugu

Chairman and CEO
Sysmex Corporation

The Ebola crisis served as a stark reminder of the devastating potential of infectious diseases. But when that epidemic finally subsides, there remains countless other infections threatening the health of the world's poorest populations. By partnering with GHIT, the Wellcome Trust hopes to bring the very best of Japanese science to bear in tackling this critical unmet need.

Stephen Caddick, PhD

Director of the Innovations division
Wellcome Trust

Globalization has connected populations around the world in unprecedented ways. It has also increased the risk of infectious diseases spreading around the globe. We believe it is ANA's social responsibility to support the GHIT Fund.

Osamu Shinobe

President and CEO
ANA

The Ebola crisis reinforced for us both the urgent need for global health innovation as well as how effectively industry and the global health community can mobilize together to create and deliver new solutions. Partnering with the GHIT Fund helps us engage even more meaningfully in global health over the long term, enabling us to leverage our history of innovation.

Shigetaka Komori

Chairman and CEO
FUJIFILM Corporation

To be truly successful in tackling the global healthcare challenges we are facing, we know we can’t do it on our own. We believe collaboration is critical in finding the best solutions for patients – which is why we work with over 3,000 external partners around the world. We are delighted to join this public-private partnership to advance innovation in Japan for the patients who are suffering from neglected diseases in developing countries.

Sir Andrew Witty

CEO
GlaxoSmithKline

We aspire to make lasting difference in human health by addressing the comprehensive health needs of people living in underserved regions of the world. We embrace this opportunity to support the GHIT Fund as it continues to develop innovative solutions that can positively impact the lives of so many people.

Paul Stoffels, MD

Chief Scientific Officer
Johnson & Johnson

We share GHIT’s sense of urgency about the need to deliver new tools to those suffering from diseases for which there are currently no adequate treatments. CSV (Creating Shared Value) Management based on Our Unique Business Structure is the important components of our Mid-term Business Plan. Therefore, the GHIT Fund who is striving to build global partnerships creates the perfect opportunity for us to do just that.

Nobuo Hanai, PhD

President and CEO
Kyowa Hakko Kirin Co., Ltd.

Merck is committed to fighting against schistosomiasis in Africa through the Praziquantel Donation Program and our leadership role in the Pediatric Praziquantel Consortium – a formulation program including several partners and partially funded by the GHIT. The aim of this international partnership is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children. Our engagement with the GHIT Fund accelerates our progress towards developing a potential treatment solution for this vulnerable population.

Belén Garijo, MD

Member of the Executive Board & CEO Healthcare
Merck KGaA

We are honored to make our chemical compound library available to global health R&D through the GHIT Fund. Our partnership between PDPs and the GHIT will move the dial on battling drug-resistance and creating new treatments for the infectious diseases that burden the developing world.

Masayuki Mitsuka, PhD

President & Representative Director
Mitsubishi Tanabe Pharma Corporation

Since our founding, we have sought to leverage technology to prevent suffering and improve the health of people around the world. Globally, we know that antimicrobial resistance is a critical challenge. MDR-TB alone presents a massive burden on communities and economies worldwide. Joining forces with GHIT amplifies the ability of our leadership and technology to contribute to the fight against infectious diseases.

Yoshihiko Sano

President
Nipro Corporation

Otsuka Pharmaceutical, based on our corporate philosophy of ‘Otsuka-people creating new products for better health worldwide’, and on our scope as a total healthcare company, focuses on the creation of uniquely innovative products that address people’s unmet medical needs that arise from pressing global healthcare problems. Our commitment to develop new treatments for tuberculosis, led to investments for over thirty years in basic and clinical research that resulted in the creation of delamanid, one of the first new anti-tuberculosis agents in almost half a century. Henceforth, through our participation in the GHIT Fund, it is our sincere belief that we can contribute further to improving the health of people across the world.

Tatsuo Higuchi

President and Representative Director
Otsuka Pharmaceutical Co., Ltd.

We are dedicated to providing innovative and effective pharmaceutical solutions to people not only in Japan but also around the world through research and development of new drugs. Participation in the GHIT Fund helps us be more globally active and bring our leading-edge technologies to fight against infectious diseases in the developing world.

Masayo Tada

Representative Director, President and CEO
Sumitomo Dainippon Pharma Co., Ltd.

NEW COMMITMENTS, EXPANDING CAPACITY

We launched the GHIT Fund in 2013 as a $100 million fund.
Today, as a result of new and renewed commitments, our funding exceeds $140 million.

WE WILL DELIVER.

Critically needed innovations with the potential to save millions of lives are no longer just
aspirations—they are moving steadily through the pipeline.

PDF Version of GHIT Annual Report 2015
Download